Actiq Paragraph IV Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
The first ANDAs with Paragraph IV certifications for Cephalon's Actiq lozenges 0.4 mg and 0.2 mg were filed Oct. 6 and Oct. 29, respectively, FDA said in its Dec. 16 updated list of Paragraph IV filings